August 9, 2016Time: 4:30 PM ETListen via Internet: http://ir.tobiratx.com/ Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=71384&k=54817826
Toll-free: 1 (855) 638-8858 International: +1 (707) 294-1299 Access code: 59149594
A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 59149594.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.
Tobira® is a registered trademark owned by
©2016 Tobira Therapeutics, Inc. All Rights Reserved.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD +1 (650) 351-5013 email@example.com BrewLife Media Contact Kelly Boothe+1 (415) 946-1076 firstname.lastname@example.org
News Provided by Acquire Media